Trivalent chromium and the diabetes prevention program

Medical Hypotheses

Volumn 49, Issue 1, 1997, Pages 47-49

  Linday, L A ^a,b  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMIUM PICOLINATE; METFORMIN; ORAL ANTIDIABETIC AGENT; TROGLITAZONE;

ADULT; ALTERNATIVE MEDICINE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0030882814     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(97)90251-6     Document Type: Article

References (20)

1. Diabetes prevention study. The New York Times 1996; June 12, Sect. C: 10 (col. 5).
2. Keen H. Insulin resistance and the prevention of diabetes mellitus (editorial). N Engl J Med 1994; 331: 1226-1227.
3. Anderson R, Cheng N, Bryden N et al. Beneficial effects of chromium for people with type II diabetes (abstract). Diabetes 1996; 45 (2 Suppl): 124A.
4. Heller R F, Heller R F. Profactor-H (elevated circulating insulin): The link to health risk factors and diseases of civilization. Med Hypotheses 1995; 45: 325-330.
5. Jovanovic-Peterson L, Gutierrez M, Peterson C M. Chromium supplementation for gestational diabetic women (GDM) improves glucose tolerance and decreases hyperinsulinemia (abstract). Diabetes 1996; 45 (2 Suppl): 337A.
6. Mahdi G S. Coronary risk factors in people from the Indian subcontinent (letter). Lancet 1995; 345: 982-983.
7. McCarty M F. Homologous physiological effects of phenformin and chromium picolinate. Med Hypotheses 1993; 41: 316-324.
8. Mertz W. Chromium in human nutrition: A review. J Nutr 1993; 123: 626-633.
9. Nielsen F H. Chromium. In: Shils M E, Olson J A, Shike M, eds. Modern Nutrition in Health and Disease, 8th edn. Philadelphia: Lea & Febiger, 1994: 264-268.
10. Bailey C J, Path M R C, Turner R C. Metformin. N Engl J Med 1996; 334: 574-579.
11. Clark C M Jr, Adlin V, eds. Risks and benefits of intensive management in non-insulin-dependent diabetes mellitus; The Fifth Regenstrief Conference. Ann Intern Med 1996; 124 (1 pt 2): 81-186.
12. Godsland I F, Stevenson J C. Insulin resistance: syndrome or tendency? Lancet 1995; 346: 100-103.
13. Heller R F, Heller R F. Hyperinsulinemic obesity and carbohydrate addiction: the missing link is the carbohydrate frequency factor. Med Hypotheses 1994; 42: 307-312.
14. Reaven G M, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374-381.
15. Kolata G. On fringes of health care, untested therapies thrive. The New York Times 1996; June 17, Sect. A: 1 (col. 1).
16. Stearns DM, Wise J P Sr, Patierno Sr, Wetterhahn K E. Chromium (III) picolinate produces chromosome damage in Chinese hamster ovary cells. FASEB J 1995; 9: 1643-1648.
17. Stearns D M, Belbruno J J, Wetterhahn K E. A prediction of chromium (III) accumulation in humans from chromium dietary supplements. FASEB J 1995; 9: 1650-1657.
18. Huszoneck J. Over-the-counter chromium picolinate (letter). Am J Psychiatry 1993; 10: 1560-1561.
19. Nolan J J, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994; 331: 1188-1193.
20. Iwamoto Y, Kuzuya, T, Matsuda A et al. Effects of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 1991; 14: 1083-1086.